Popular on EntSun
- The World's No.1 Superstar Dies After Choking on a French Fry - 146
- NEMTAC Announces New Board of Directors Officers for 2024-2025 - 101
- One Dream, Three Amazing Journeys… On and Off the Basketball Court
- Vantiva Receives 2024 RDK "Distinguished Leader Award"
- FEM Provides a Safe, Free Space for Female Business Owners
- Immigrant Artists Explore Cultural, Historical and Social Experiences in "Unlocked Identities" Exhibition
- Diana Partners With OpsVeda To Leverage AI-ML To Get Closer To Its Consumers
- Human Resources Strategy Forum Celebrates 30 Years Empowering Leaders, Shaping the Next Generation of HR Innovators
- AVTECH Announces New Room Alert Bundles for Heat Safety and Enhanced Indoor Air Quality Monitoring
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
Similar on EntSun
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
- Use Bitcoin to Earn Bitcoin - Innovative Layer 2 Solution for Bitcoin
- Trade Meter AI Featured on StartUpers Podcast's Pilot Episode: A Deep Dive into the Future of AI-Powered Stock Analysis
- Jessica Perrone and HerFinIQ Announce B.I.G. Investors Club: Empowering Women Towards Financial Independence Through Education and Community
- Lightstone Solutions Announces Appointment of Brian Obney as Chief of Staff and Director of Due Diligence
NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
EntSun News/11036279
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval
RADNOR, Pa. - EntSun -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on EntSun News
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on EntSun News
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on EntSun News
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Sar Kamler Releases Debut Album: Butterfly: Colors of Armenian Duduk
- Pro Sound League: The Next Big Movement in Music Launching in 2025 – Join Us!
- Celebrate the Holidays with Free Flute and Guitar Concerts: "May Your Days Be Merry & Bright"
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on EntSun News
- Family Story Day Returns to El Paso
- Agency ends 3rd quarter with Welcoming 16 Hand Selected Influencers out of Thousands of Applicants
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- Mezzo-Soprano Tracie Luck Returns to the Weinberg Center Stage
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Media
0 Comments
Latest on EntSun News
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Sixx Pack Krew (SPK): Atlanta's Rising Collective in Music, Gaming, and Influence
- Renowned Beauty Brand 'Natalia Megan Beauty' Unveils Latest Product Additions
- Get in the Halloween Spirit at Rare Books LA Union Station
- Solution Tavern Opens Bringing Drinks, Sports, Trivia, and More to Local Neighborhood!
- Parler Unveils PlayTV: A New Playground for Content Creators!
- Arena Rock Tribute Will Rock Turning Stone - Final Show
- Indie Gospel Recording Artist Dianna Hobbs Signs with Halo Management and Releases New Single 'Don't Know Why'—OUT NOW
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- Grand opening of the ResC4EU platform to support companies withstanding supply chain disruptions
- Vertical Horizon Celebrates 25 Years of "Everything You Want" at the Weinberg Center
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- Columbus Fashion Council Announces Bruce & Glen Proctor as Headline Designer for Finale Runway Show
- "Live Courageously" With Host John Duffy will Have Guest Tom Ohmer an Actor From the Stage and TV
- The Ultimate Guide to Buying Historic Luxury Homes in Winter Park, FL Now Available
- And The Winner Is: Special Request Ft Rey T (AKA) Reynard Thomas
- Sky Lites Drone Shows with LASERs
- Don Barnhart Set to Bring the Laughter to Delirious Comedy Club In Downtown Las Vegas
- Junetini to Host 'Meet, Greet & Tasting' at the Ultimate Women's Expo 2024
- Allegiant Management Group Launches New Website Following Recent Rebranding